Pailles plant procurement: 51 meetings, one lowest bidder, questions remain

Pailles treatment plant's procurement file runs to 51 evaluation meetings, and what it reveals is as telling as what it withholds. A joint venture between Sotravic and BWI advanced to negotiations after the Central Procurement Board approved talks with the lowest ranked bidder among two substantially responsive submissions. That sequence is documented. Much of what has been said about it publicly is not. Public debate has centered on whether a fresh tender would have delivered better value. The available documentation does not answer that question. It logs evaluation steps and tracks an internal estimate's movement, but withholds the negotiated price and offers no comparison to alternative bids under the final scope. One strand of media framing has claimed negotiations produced a price well above the Bid Evaluation Committee's updated Rs600.7 million estimate and that the result failed to represent value for money. The same framing proposes a new bidding exercise as the obvious remedy. That conclusion rests on assumptions the record does not verify. The estimate itself jumped sharply, from earlier figures of approximately MUR 429 million to 450 million, up to Rs600.7 million. The excerpt provides no technical explanation for the change. It offers no breakdown of cost drivers, no account of scope effects from addenda and clarifications, and no market benchmarks showing what the revised scope should cost. A number moved significantly, and the documentation is silent on why. By contrast, the process details cut against claims that a restart would necessarily improve outcomes. After those 51 evaluation meetings, only two bids qualified as substantially responsive. Only the joint venture advanced as the lowest bidder approved for negotiation. The procurement framework also allowed post-evaluation negotiation, placing the later price discussion inside the designed procedure rather than outside it. A re-tender does not guarantee more compliant submissions or lower prices; it guarantees another round of the same process. Without the negotiated figure, competing bids, or evidence that fresh bidding would draw compliant offers at or below Rs600.7 million, broad value judgments remain unsupported. The narrower and more defensible reading is straightforward: the record confirms the joint venture cleared responsiveness tests and reached negotiations through the established framework. The case for a better-priced re-tender, whatever its political appeal, remains undemonstrated by the documents at hand. The real question the file leaves open is whether the scope changes that drove the estimate upward were themselves necessary, and whether any future procurement exercise would address that underlying issue or simply repeat it.